Texas Cancer Agency Stops Grants

The Cancer Prevention and Research Institute of Texas has agreed to stop awarding new grants until it addresses concerns about the integrity of is review process.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, KUEBIAt the written request of Texas governor Rick Perry (R), the state’s embattled $3 billion dollar cancer research funding agency this week announced a moratorium on new grants, reported ScienceInsider. The agency will award no more grants until it properly addresses continued concerns about the legitimacy of its review procedures.

The Cancer Prevention and Research Institute of Texas (CPRIT) has been in trouble since May 2012, when its chief scientific officer, the Nobel Prize-winning biochemist Alfred Gilman, announced he would quit over grave concerns about the integrity of the agency’s peer-review procedure. Gilman stepped down in October, and was quickly followed by the chair of the review council and scores of peer reviewers.

Two more top officials, including the agency’s executive director, Bill Gimson, have resigned in the past few weeks amid allegations about possible criminal activity involving a round of grants awarded to companies owned by Dallas businessman David Shanahan, a major campaign contributor to Texas Governor Perry and Lieutenant Governor David Dewhurst.

Following the commencement of a civil investigation, CPRIT this week received ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Dan Cossins

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide